Literature DB >> 6233981

Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro.

B A Kamen, B Eibl, A Cashmore, J Bertino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6233981     DOI： 10.1016/0006-2952(84)90298-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  29 in total

1.  Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.

Authors:  F V Fossella; R J Winn; P Y Holoye; B Hallinan; M N Raber; K Hoelzer; J A Young; J Readling; B Bowers; W K Hong
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

2.  Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.

Authors:  R W Carlson; J H Doroshow; O O Odujinrin; M S Flam; M Malec; K R Lamborn
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

3.  Cellular transport of CI-980.

Authors:  K E Hook; S A Przybranowski; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome.

Authors:  P Rogers; C J Allegra; R F Murphy; J C Drake; H Masur; D G Poplack; B A Chabner; J E Parrillo; H C Lane; F M Balis
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

5.  Trimetrexate: a new antifol entering clinical trials.

Authors:  P J O'Dwyer; D D Shoemaker; J Plowman; J Cradock; A Grillo-Lopez; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.

Authors:  Charles D Blanke; Kari Chansky; Kathy L Christman; Scott A Hundahl; Brian F Issell; Peter J Van Veldhuizen; G Thomas Budd; James L Abbruzzese; John S Macdonald
Journal:  Am J Clin Oncol       Date:  2010-04       Impact factor: 2.339

Review 7.  Clinical pharmacokinetics and pharmacology of trimetrexate.

Authors:  J L Marshall; R J DeLap
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

8.  A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.

Authors:  L B Grochow; D A Noe; D S Ettinger; R C Donehower
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.

Authors:  R S Witte; B Y Yeap; D L Trump
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 10.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.